Simcere Pharmaceutical Group Limited (HKG:2096)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
11.53
-0.14 (-1.20%)
At close: Mar 13, 2026

HKG:2096 Ratios and Metrics

Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
29,80317,65317,61130,91423,62823,347
Market Cap Growth
55.79%0.24%-43.03%30.83%1.20%-
Enterprise Value
28,21815,63916,20529,37123,20926,834
Last Close Price
11.536.986.4210.848.238.09
PE Ratio
29.4022.6322.3729.3812.7729.36
Forward PE
20.6714.3512.1129.0426.6318.00
PS Ratio
3.832.502.424.323.854.36
PB Ratio
3.762.352.213.832.983.68
P/TBV Ratio
4.772.812.514.163.103.89
P/FCF Ratio
26.2016.04-27.04--
P/OCF Ratio
19.5011.93105.8320.19-203.24
PEG Ratio
-1.121.121.121.12-
EV/Sales Ratio
3.622.222.234.113.785.01
EV/EBITDA Ratio
16.4710.8315.9031.8644.7629.79
EV/EBIT Ratio
20.3312.9720.6942.8581.0337.66
EV/FCF Ratio
24.8114.21-25.69--
Debt / Equity Ratio
0.170.170.200.210.250.62
Debt / EBITDA Ratio
0.790.841.431.723.504.10
Debt / FCF Ratio
1.191.17-1.49--
Net Debt / Equity Ratio
-0.20-0.10-0.08-0.16-0.080.01
Net Debt / EBITDA Ratio
-0.97-0.54-0.64-1.37-1.300.03
Net Debt / FCF Ratio
-1.39-0.711.77-1.101.33-0.10
Asset Turnover
0.580.590.610.600.470.51
Inventory Turnover
1.911.802.844.013.592.94
Quick Ratio
1.531.731.761.691.511.48
Current Ratio
1.732.002.101.841.631.85
Return on Equity (ROE)
12.45%10.26%9.94%13.62%25.41%19.49%
Return on Assets (ROA)
6.50%6.33%4.11%3.62%1.38%4.23%
Return on Invested Capital (ROIC)
19.48%15.63%10.83%10.15%4.14%11.15%
Return on Capital Employed (ROCE)
13.90%12.90%8.70%7.80%3.30%8.10%
Earnings Yield
3.24%4.42%4.47%3.40%7.83%3.41%
FCF Yield
3.82%6.23%-2.08%3.70%-2.14%-1.30%
Dividend Yield
1.58%2.44%2.74%1.67%2.24%2.20%
Payout Ratio
45.61%54.76%58.65%42.04%25.96%-
Buyback Yield / Dilution
4.18%3.40%0.45%-0.34%-9.14%-2.03%
Total Shareholder Return
5.75%5.83%3.19%1.32%-6.91%0.18%
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.